Jasbir Seehra
Known title: Chief Executive OfficerCIK: 0001732369
Associated companies
Transaction History
| KROS | ▲ Buy | Option Exercise | 55,000 | $17K | 4/2/2026 | View on chart |
| KROS | ▼ Sell | Open Market | 7,015 | $113K | 2/19/2026 | View on chart |
| KROS | ▲ Buy | Grant | 90,500 | $0 | 9/3/2025 | View on chart |
| KROS | ▲ Buy | Option Exercise | 49,367 | $15K | 4/4/2025 | View on chart |
| KROS | ▲ Buy | Option Exercise | 4,000 | $2K | 4/8/2023 | View on chart |
| KROS | ▲ Buy | Option Exercise | 5,000 | $2K | 6/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial
Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial. Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.